Brief: Bioporto Says Expects To Complete Clinical Study And Submit A De Novo Application To FDA For Pediatric Use Of NGAL Test This Summer

BioPorto A/S

03/03/2021 17:47

March 3 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-PIPELINE UPDATE FROM BIOPORTO
    * EXPECTS TO COMPLETE CLINICAL STUDY AND SUBMIT A DE NOVO
APPLICATION TO FDA FOR PEDIATRIC USE OF NGAL TEST™ THIS SUMMER
    * BIOPORTO AWAITS US TEST RESULTS FOR RAPID GRAD-BASED
SARS-COV-2
ASSAY
    * IF RESULTS FOR RAPID GRAD-BASED SARS-COV-2 ASSAY IS
POSITIVE,
COMPANY WILL PROCEED TOWARDS EUA AND CE MARK IN Q2 OF 2021

Source text for Eikon:  ID:nGNEbbWgy6 
Further company coverage:  BIOPOR.CO 

 ((Reuters.Briefs@thomsonreuters.com;))